XML 46 R25.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Segment and Geographic Information (Notes) | 12 Months Ended
--- | ---
Dec. 31, 2015
Segment Reporting [Abstract] |
Reporting Segments | Segment and Geographic Information The structure of the Company’s internal organization is divided into the following reportable segments, which are also the Company’s operating segments: E&C, D&S and BioMedical. The Company’s reportable segments are business units that are each managed separately because they manufacture, offer and distribute distinct products with different production processes and sales and marketing approaches. The E&C and D&S segments manufacture products used primarily in energy-related and industrial applications, such as the separation, liquefaction, distribution and storage of hydrocarbon and industrial gases. The BioMedical segment supplies cryogenic and other equipment used in the medical, biological research and animal breeding industries. Due to the nature of the products that each segment sells, intersegment sales are not material. Corporate includes operating expenses for executive management, accounting, tax, treasury, corporate development, human resources, information technology, investor relations, legal, internal audit, risk management and share-based compensation expenses that are not allocated to the reporting segments. The Company evaluates performance and allocates resources based on operating income or loss from continuing operations before interest expense, net, financing costs amortization, foreign currency loss (gain), income tax expense, net and noncontrolling interests, net of taxes. The accounting policies of the reportable segments are the same as those described in Note 2. Segment Financial Information
| Year Ended December 31, 2015
| Energy & Chemicals |  | Distribution & Storage |  | BioMedical |  | Corporate |  | Total
Sales to external customers | $ | 330,968 |  |  | $ | 487,557 |  |  | $ | 221,635 |  |  | $ | — |  |  | $ | 1,040,160 |
Depreciation and amortization expense | 11,805 |  |  | 18,289 |  |  | 12,039 |  |  | 3,315 |  |  | 45,448 |
Operating (loss) income (1) | (8,138 | ) |  | 41,732 |  |  | (164,284 | ) |  | (52,533 | ) |  | (183,223 | )
Total assets (2) | 251,810 |  |  | 689,112 |  |  | 224,443 |  |  | 36,611 |  |  | 1,201,976 |
Capital expenditures | 4,074 |  |  | 36,835 |  |  | 3,849 |  |  | 2,281 |  |  | 47,039 |
| Year Ended December 31, 2014
| Energy & Chemicals |  | Distribution & Storage |  | BioMedical |  | Corporate |  | Total
Sales to external customers | $ | 388,018 |  |  | $ | 578,806 |  |  | $ | 226,128 |  |  | $ | — |  |  | $ | 1,192,952 |
Depreciation and amortization expense | 9,649 |  |  | 16,749 |  |  | 13,842 |  |  | 2,936 |  |  | 43,176 |
Operating income (loss) (3) | 79,665 |  |  | 85,213 |  |  | 25,694 |  |  | (52,415 | ) |  | 138,157 |
Total assets (2) | 322,936 |  |  | 666,451 |  |  | 396,320 |  |  | 76,356 |  |  | 1,462,063 |
Capital expenditures | 24,834 |  |  | 29,583 |  |  | 3,484 |  |  | 4,234 |  |  | 62,135 |
| Year Ended December 31, 2013
| Energy & Chemicals |  | Distribution & Storage |  | BioMedical |  | Corporate |  | Total
Sales to external customers | $ | 318,510 |  |  | $ | 592,616 |  |  | $ | 266,312 |  |  | $ | — |  |  | $ | 1,177,438 |
Depreciation and amortization expense | 8,564 |  |  | 15,237 |  |  | 14,618 |  |  | 1,970 |  |  | 40,389 |
Operating income (loss) | 59,671 |  |  | 93,560 |  |  | 33,039 |  |  | (50,273 | ) |  | 135,997 |
Total assets (2) | 277,760 |  |  | 676,484 |  |  | 431,763 |  |  | 75,623 |  |  | 1,461,630 |
Capital expenditures | 34,194 |  |  | 32,039 |  |  | 3,370 |  |  | 2,982 |  |  | 72,585 |
_______________
(1) | Includes asset impairment charges of $255,116 for the year ended December 31, 2015, attributed to E&C - $68,796, D&S - $2,020 , and BioMedical - $184,300.
(2) | Corporate assets consist primarily of cash, cash equivalents and deferred income taxes.
(3) | The BioMedical segment’s operating income included recovery of $5,003 increasing operating income for the year ended December 31, 2014 from an escrow settlement for breaches of representations and warranties relating to warranty costs (which are in excess of the settlement amount) for certain product lines acquired from AirSep in 2012.
The following table represents the changes in goodwill by segment:
| Energy & Chemicals |  | Distribution & Storage |  | BioMedical |  | Total
Balance at January 1, 2014 | $ | 83,215 |  |  | $ | 160,054 |  |  | $ | 155,636 |  |  | $ | 398,905 |
Foreign currency translation adjustments and other | 130 |  |  | (2,806 | ) |  | — |  |  | (2,676 | )
Goodwill acquired during the year | 9,293 |  |  | — |  |  | — |  |  | 9,293 |
Balance at December 31, 2014 | 92,638 |  |  | 157,248 |  |  | 155,636 |  |  | 405,522 |
Foreign currency translation adjustments and other | (162 | ) |  | (1,909 | ) |  | 184 |  |  | (1,887 | )
Goodwill acquired during the year | — |  |  | 10,601 |  |  | — |  |  | 10,601 |
Impairment loss | (64,603 | ) |  | — |  |  | (131,243 | ) |  | (195,846 | )
Balance at December 31, 2015 | $ | 27,873 |  |  | $ | 165,940 |  |  | $ | 24,577 |  |  | $ | 218,390 |
Accumulated goodwill impairment loss | $ | 64,603 |  |  | $ | — |  |  | $ | 131,243 |  |  | $ | 195,846 |
Product Sales Information
| Year Ended December 31,
| 2015 |  | 2014 |  | 2013
Energy & Chemicals |  |  |  |  |
Natural gas processing (including petrochemical) applications | $ | 180,909 |  |  | $ | 208,706 |  |  | $ | 175,397 |
Liquefied natural gas applications | 136,049 |  |  | 143,870 |  |  | 114,567 |
Industrial gas applications | 14,010 |  |  | 35,442 |  |  | 28,546 |
Total Energy & Chemicals | 330,968 |  |  | 388,018 |  |  | 318,510 |
Distribution & Storage |  |  |  |  |
Bulk industrial gas applications | 203,834 |  |  | 204,214 |  |  | 241,291 |
Packaged gas industrial applications | 167,814 |  |  | 164,966 |  |  | 158,293 |
Liquefied natural gas applications | 115,909 |  |  | 209,626 |  |  | 193,032 |
Total Distribution & Storage | 487,557 |  |  | 578,806 |  |  | 592,616 |
BioMedical |  |  |  |  |
Respiratory therapy | 132,321 |  |  | 141,273 |  |  | 175,233 |
Life sciences | 64,641 |  |  | 65,948 |  |  | 61,493 |
Commercial oxygen generation | 24,673 |  |  | 18,907 |  |  | 29,586 |
Total BioMedical | 221,635 |  |  | 226,128 |  |  | 266,312 |
Total | $ | 1,040,160 |  |  | $ | 1,192,952 |  |  | $ | 1,177,438 |
Geographic Information Net sales by geographic area are reported by the destination of sales. Net property, plant and equipment by geographic area are reported by country of domicile.
| Sales for the Year Ended December 31,
| 2015 |  | 2014 |  | 2013
United States | $ | 513,691 |  |  | $ | 560,846 |  |  | $ | 479,067 |
Foreign |  |  |  |  |
China | 109,978 |  |  | 188,047 |  |  | 231,143 |
Other foreign countries | 416,491 |  |  | 444,059 |  |  | 467,228 |
Total Foreign | $ | 526,469 |  |  | $ | 632,106 |  |  | $ | 698,371 |
Total | $ | 1,040,160 |  |  | $ | 1,192,952 |  |  | $ | 1,177,438 |
| Property, plant and equipment, net as of December 31,
| 2015 |  | 2014 |  | 2013
United States | $ | 153,987 |  |  | $ | 163,425 |  |  | $ | 146,610 |
Foreign |  |  |  |  |
Czech Republic | 19,742 |  |  | 22,511 |  |  | 23,623 |
China | 79,691 |  |  | 57,580 |  |  | 38,569 |
Germany | 12,246 |  |  | 13,495 |  |  | 14,618 |
Other foreign countries | 611 |  |  | 634 |  |  | 785 |
Total Foreign | $ | 112,290 |  |  | $ | 94,220 |  |  | $ | 77,595 |
Total | $ | 266,277 |  |  | $ | 257,645 |  |  | $ | 224,205 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration